MAP2K7 and acute myeloid leukemia: The Raf inhibitor Sorafenib [94], the MEK inhibitor GDC-0973 (Cobimetinib) [95], the ERK1/2 inhibitor LY3214996 (Temuterkib) [96], a pan-class I PI3K inhibitor Rigosertib [97], Akt inhibitor MK2206 [98] and Akt/Erk inhibitor ONC201 [99] may be accessible for AML patients within the framework of clinical trials alone or in combination with other chemotherapeutic agents.